Craft

Molecular Partners

Stock Price

CHF5.6

2024-10-29

Market Capitalization

CHF185.9 M

2024-10-29

Molecular Partners Summary

Company Summary

Overview
Molecular Partners is a biopharmaceutical company that focuses on the discovery, development, and commercialization of biopharmaceutical products for the treatment of wet age-related macular degeneration and diabetic macular edema. It also develops ankyrin repeat protein therapies used in ophthalmology, oncology, inflammation, and other therapeutic treatments.
Type
Public
Status
Active
Founded
2004
HQ
Zürich-Schlieren, CH | view all locations
Website
https://www.molecularpartners.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Michael Tobias Stumpp

    Michael Tobias Stumpp, Chief Operating Officer and Member of the Management Board

  • Patrick Amstutz

    Patrick Amstutz, Chief Executive Officer and Director

  • Andreas Emmenegger

    Andreas Emmenegger, Chief Financial Officer and Member of the Management Board

  • Nicolas Leupin

    Nicolas Leupin, Chief Medical Officer and Member of the Management Board

LocationsView all

3 locations detected

  • Zürich-Schlieren HQ

    Switzerland

    14 Wagistrasse

  • Cambridge, MA

    United States

    245 Main St

  • Concord, MA

    United States

    33 Bradford St

Molecular Partners Financials

Summary Financials

Net income (FY, 2025)
(CHF61.7M)
Cash (FY, 2025)
CHF82.7M
EBIT (FY, 2025)
(CHF58.1M)
Enterprise value
$125.0M

Footer menu